Fennec Pharmaceuticals Inc. (FENC)
NasdaqCM: FENC
· 即時價格 · USD
12.39
-0.16 (-1.27%)
收盤價： Sep 04, 2026, 3:59 PM
12.39
+0.00%
盤後: 7:30 PM
股價、關鍵數字和最新消息，都在這一頁。
Fennec Pharmaceuticals Inc.（FENC）股價、分析與資料
-1.27% (1D)
| 買價 | 8.91 |
| 市值 | 434M |
| 營收 (ttm) | 59.2M |
| 淨利（ttm） | -3.25M |
| 1.10 | |
| -0.12 | |
| n/a | |
| 13.01 | |
| P/B (ttm) | 10.23 |
| P/S (ttm) | 7.34 |
| 財報日期 | Nov 12, 2026 |
| 賣價 | 15.98 |
| 成交量 | 212,436 |
| 20 日平均成交量 | 231,546 |
| 開盤價 | 12.45 |
| 前收盤價 | 12.55 |
| 當日區間 | 12.29 - 12.60 |
| 52 週範圍 | 5.65 - 13.25 |
| 分析師 | n/a |
| 目標價 | 18 (45.28%) |
| 股利 | n/a |
| 除息日 | n/a |
關於 FENC
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation,...
完整的公司簡介財務表現
Fennec Pharmaceuticals 在 2025 年的營收為 44.64M，較前一年的 47.54M 減少 -6.09%。 淨利為 -9.74M，較前期增加 2,134.17%。
財務報表財報驚奇
Fennec Pharmaceuticals 已於 Aug 11, 2026 公布季度財報：
- 營收為 $15.11M 低於預期 $0, 年增 72.64% 成長.
- 每股盈餘為 0.05 超出預期 0.03, 年增 145.45% 成長.
第 1 頁，共 2 頁